Noxopharm is a Group comprising Noxopharm Ltd, Nyrada Inc, and NoxAsia Ltd with offices in Sydney, New York and Hong Kong. The Group's drug pipeline contains 4 drug candidates: Veyonda®, NYX-104, NYX-205, NYX-330. Veyonda® is being developed as an enhancer of radiotherapy across a range of cancers, including prostate cancer patients being treated with both standard external beam radiotherapy and intravenous radionuclide (177lutetium-PSMA-617) therapy; NYX-104 is a neuroprotectant being developed to limit secondary brain damage (glutamate-induced excitotoxicity) following ischaemic stroke and concussion; NYX-205 is an anti-inflammatory being developed for the treatment of peripheral neuropathy associated with diabetes and chemotherapy; NYX-330 is a PCSK9 inhibitor being developed for the treatment of high blood LDL cholesterol levels that fail to respond adequately to statin therapy alone.

Veyonda® is the first pipeline product, previously known as NOX66. It is currently in clinical trials. It has also been trialled as an enhancer of chemotherapy across a range of cancers.

Media Releases

Latest Company News


Videos

Feb 2020 05:15 PM
Noxopharm (ASX:NOX) LuPIN tria..
25 Feb 2020 - Noxopharm Limited (ASX:NOX) Chief Medical Officer, Dr Gisela Mautner, talks about results from the company's LuPIN trial in prostate cancer, evaluating its lead product candidate, Veyonda, in combination with 177Lu-PSMA-617, a radiopharmaceutical therapy, in 56 patients with late-stage prostate cancer.

Contact Information